GENENTECH, INC for GENENTECH INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Cyber security, Transpacific partnership
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| ELI KOGAN | Asst. Director |
Trade (domestic/foreign) TRD
Proposed changes in global patent protections, compulsory license issues in India
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| ELI KOGAN | Asst. Director |
Taxation/Internal Revenue Code TAX
tax reform, general corporate and international taxation; Genteral tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned U.S. corporations; Research and Development Tax credit; Issues related to comprehensive tax reform, tax treatment of and tax extenders, including R&D tax credit. Corporate tax reform issues. International trade issues and patent protection abroad.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asst. Director |
| ELI KOGAN | Asst. Director |
Health Issues HCR
Reimbursement issues; Issues relating to the treatment of biologics in international health programs; Issues related to the implementation of the Affordable Care Act of 2010; proposed cuts to Part B reimbursement. 340b reimbursement policy; Implementation of H.R. S. 959, "Pharmaceutical Compounding Quality and Accounting Act", H.R 1416, "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", H.R. 1919, "Safeguarding America's Pharmaceuticals Act"
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Asst. Director |
Medicare/Medicaid MMM
Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues; Implementation issues related to Medicare and Medicaid reimbursement, fees assessd on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and bilogics approval. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis; Concerns regarding Medicare payment policies for Part B drugs; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B program, dual eligible demonstratins and relaed provisions Part B; Medicare reimbursement for physicians, and provisions of The Affordable Care Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asst. Director |
| DARIN GARDNER | Sr. Director Government Affairs |
| KATHERINE RAAB | Asst. Director |
Budget/Appropriations BUD
Issues related to FDA & HHS program funding, FY14 Labor Health and Human Services, and Education, and Related Agenciesand H.R 2410, FY14 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bills.; FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenca, HIV/AIDS programs, hepatitis screening, care and treatment, and access to breast cancer treatment.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asst. Director |
| DARIN GARDNER | Sr. Director Government Affairs |
| EVAN MORRIS | VP Government Affairs |
Pharmacy PHA
Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| KATHERINE RAAB | Asst. Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.